The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.
This is Phase I of a a two phased multi-step mandatory down select solicitation. Interest for Phase I is due to the contracting officer no later than 2:00 PM EST February 7, 2025.
The steps in Phase I are as follows: